Preparing to bring multiple new products to market, NutraNomics is a dietary supplement research and development company that has been working on new formulations for over 18 years. At the helm of NutraNomics is CEO Dr. Tracy Gibbs, who traveled worldwide and studied the science of medicines derived from natural sources. His particular expertise has been finding ways to treat diseases that may be caused by or made worse by enzyme deficiencies. So, if you suffer from an enzyme deficiency, your body is not properly extracting all the nutrients you need from your food, and this can lead to a number of health problems.
Found in all living cells, enzymes are large organic molecules that act as catalysts; in other words they aid and increase the rates of biochemical reactions. Specifically, the biochemical reactions are a necessary part of the breakdown and regenerative process of life. Digestive enzymes break down the food we eat, and the way we cook or process food may destroy the enzymes needed to break down the food properly, thus taking enzyme supplements can aid in digesting food. For example, the enzymes amylase, lipase, and protease are all produced in the pancreas, and each plays a role in the digestive process: amylase in the breakdown of carbohydrates, lipase in the breakdown of fats, and protease in the breakdown of proteins. All three of these particular enzymes can also be found in a number of raw fruits and vegetables, nuts, and grains.
One of the primary innovations in NutraNomics product pipeline is its patented Assimilation Enhancing System (AES) formulation. AES is a combination of enzymes with mineral cofactors designed to enhance the activity and efficiency of the enzymes. This ensures the AES is active throughout the digestive process as well as in the blood stream. Protein, carbohydrates, and fats contained in a product are completely hydrolyzed, which releases the vitamins, minerals, and bioactive nutrients more readily, causing them to be assimilated in the body quicker. This will also cause proteins to become more bio-available to the body. Because AES has been shown to be absorbed by the bloodstream, science also points to its ability to potentially lower triglyceride levels, blood sugar levels, uric acid levels and cholesterol levels. So overall, AES improves digestion, assimilation of nutrients, as well as overall heart health. The AES Delivery System is included in many of NutraNomics’ proprietary supplements as well as generates revenue through many licensing agreements. The company plans to pursue additional licensing arrangements throughout 2014 to boost revenue growth.
In 2013, NutraNomics also purchased the exclusive marketing and distribution rights to a natural therapeutic dietary supplement for use with cancer patients undergoing chemotherapy. FDA Phase II clinical studies were completed in December of 2013 for patients undergoing treatment of prostrate cancer. The product, called GenEpic, is formulated with 70 vitamins and minerals, 32 herbs, and 16 enzymes and phytonutrients. Phytonutrients refer to a class of chemicals found in plants that help protect plants from germs and fungal infections, and found to have similar therapeutic benefits.
Another product which had three separate case studies in 2013 is Glucozyme, a nutritional supplement developed by NutraNomics to assist in the reduction of blood glucose levels in patients with Type 2 diabetes. Essentially, by addressing the body as a whole, one can regulate and then lower blood sugar levels. Glucozyme is also being aggressively marketed this year, and a buyer in Japan is expected to make significant purchases of this product.
Overall from first quarter of 2013 compared to first quarter of 2014, sales in Japan practically tripled. NutraNomics expects to continue growing its geographic reach, and capture sales in the Philippines as well. Product sales from the company’s own web site have seen organic growth with sales increasing by 82% from the first quarter of 2014 compared to the fourth quarter of last year. The global nutraceutical market is expected to grow to $204.8 billion by 2017, and NutraNomics is certainly well positioned to capture its share.
For more information about NutraNomics, visit: www.nutranomics.com
Let us hear your thoughts: NutraNomics, Inc. Message Board
